Brief: TransThera Sciences (Nanjing) Inc And Shanghai Allist To Collaborate For NSCLC Clinical Trial
26/05/2026 16:29
BRIEF-TransThera Sciences (Nanjing) Inc And Shanghai Allist To Collaborate For NSCLC Clinical Trial May 26 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:
CO AND SHANGHAI ALLIST ANNOUNCE COLLABORATION FOR NSCLC CLINICAL TRIAL
TO CONDUCT PHASE II TRIAL OF TT-973-MS AND FIRMONERTINIB IN ADVANCED NSCLC
Further company coverage: 2617.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TransThera Sciences (Nanjing)
See all newsBrief: Transthera Sciences (Nanjing) Says Yochanra (Tinengotinib) Included In CSCO Guidelines
TransThera at 6-week high on China regulator's nod to market cancer drug
Brief: TransThera Sciences (Nanjing) Says NMPA Grants Marketing Approval For Yochanra (Tinengotinib Tablets)
Brief: Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate
TransThera Sciences jumps most in nearly four months on share buyback plan